Discovery and development of CPL207280 as new GPR40/FFA1 agonist.

导出 LinkOut

翻译打印收藏纠错

作者： Mateusz,Mach ^[1] ; Katarzyna,Bazydło-Guzenda ^[2] ; Paweł,Buda ^[3] ; Mikołaj,Matłoka ^[3] ; Radosław,Dzida ^[3] ; Filip,Stelmach ^[3] ; Kinga,Gałązka ^[3] ; Małgorzata,Wąsińska-Kałwa ^[3] ; Damian,Smuga ^[3] ; Dagmara,Hołowińska ^[3] ; Urszula,Dawid ^[3] ; Lidia,Gurba-Bryśkiewicz ^[3] ; Krzysztof,Wiśniewski ^[3] ; Krzysztof,Dubiel ^[3] ; Jerzy,Pieczykolan ^[3] ; Maciej,Wieczorek ^[3]

作者单位： Celon Pharma S.A., R&D Centre, Marymoncka 15, 05-152, Kazun Nowy, Poland. Electronic address: mateusz.mach@celonpharma.com. ^[1] Celon Pharma S.A., R&D Centre, Marymoncka 15, 05-152, Kazun Nowy, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, 61 Zwirki i Wigury Street, 02-091, Warsaw, Poland. ^[2] Celon Pharma S.A., R&D Centre, Marymoncka 15, 05-152, Kazun Nowy, Poland. ^[3]

关键词 Agonist CPL207280 Diabetes FFA1 GPR40 GSIS Insulin T2D

主题词动物(Animals);己酸盐类(Caproates);剂量效应关系, 药物(Dose-Response Relationship, Drug);人类(Humans);分子结构(Molecular Structure);大鼠(Rats);大鼠, Wistar(Rats, Wistar);受体, G-蛋白偶联(Receptors, G-Protein-Coupled);构效关系(Structure-Activity Relationship)

DOI 10.1016/j.ejmech.2021.113810

PMID 34537444

发布时间 2022-09-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

European journal of medicinal chemistry

2021年226卷

113810页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Discovery and development of CPL207280 as new GPR40/FFA1 agonist.

European journal of medicinal chemistry

相似文献

European journal of medicinal chemistry

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Discovery and development of CPL207280 as new GPR40/FFA1 agonist.

European journal of medicinal chemistry

相似文献

European journal of medicinal chemistry

相关期刊

检索历史清除